![Gareth Morgan](https://assets.euromoneydigital.com/dims4/default/499402c/2147483647/strip/true/crop/200x200+0+0/resize/800x800!/quality/90/?url=http%3A%2F%2Feuromoney-brightspot.s3.amazonaws.com%2Fd6%2F43%2F2ac6563b7d7866b2380d1e7df0e7%2Fmorgan-gareth-200.jpg)
![Richard Price](https://assets.euromoneydigital.com/dims4/default/fd13cfe/2147483647/strip/true/crop/200x200+0+0/resize/800x800!/quality/90/?url=http%3A%2F%2Feuromoney-brightspot.s3.amazonaws.com%2F76%2Ff1%2F3faf76f6924b30a7b42083be46ef%2Fprice-richard-200.jpg)
The team comprises Gareth Morgan (far right), a pharmaceutical patent and regulatory specialist who joins as a partner, and Richard Price (right), who becomes head of IP arbitration, as well as two associates.
They are particularly known for work representing generic pharmaceuticals companies: clients include Teva, Abbott Laboratories, AbbVie, Focus Pharmaceuticals, Actavis, InterMune and Healing Herbs.
Price, a qualified arbitrator, also handles trade mark and copyright work. He recently acted for Fage in the litigation over Greek yoghurt.